(4S,5R)-3-(2-bromo-5-methoxy-benzyl)-4-methyl-5-phenyl-oxazolidin-2-one | 1185737-31-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: (4S,5R)-3-(2-bromo-5-methoxy-benzyl)-4-methyl-5-phenyl-oxazolidin-2-one
• 英文别名: (4S,5R)-3-[(2-bromo-5-methoxyphenyl)methyl]-4-methyl-5-phenyl-1,3-oxazolidin-2-one
• CAS: 1185737-31-8
• 化学式: C₁₈H₁₈BrNO₃
• 分子量: 376.25
• InChiKey: LXIBSDOVCIQVOS-SJCJKPOMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  38.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (4S,5R)-3-(2-bromo-5-methoxy-benzyl)-4-methyl-5-phenyl-oxazolidin-2-one 、 2-(4-甲氧基-3-(4,4,5,5-四甲基-1,3,2-二噁硼烷-2-基)苯基)乙酸甲酯 生成 [6,4'-dimethoxy-2'-((4S,5R)-4-methyl-2-oxo-5-phenyl-oxazolidin-3-ylmethyl)-biphenyl-3-yl]-acetic acid methyl ester
  参考文献：
  名称：

  Antagonists of prostaglandin D2 receptors

  摘要：

  本文描述了一些PGD2受体拮抗剂化合物。还描述了包括上述PGD2受体拮抗剂在内的药物组合物和药物，以及使用这些PGD2受体拮抗剂的方法，单独或与其他化合物结合，用于治疗呼吸系统、心血管系统和其他PGD2依赖性或PGD2介导的疾病或症状。

  公开号：

  US08497381B2
• 作为产物：
  描述：

  (4S,5R)-(-)-4-甲基-5-苯基-2-恶唑啉酮 、 2-溴-5-甲氧基溴苄 生成 (4S,5R)-3-(2-bromo-5-methoxy-benzyl)-4-methyl-5-phenyl-oxazolidin-2-one
  参考文献：
  名称：

  Antagonists of prostaglandin D2 receptors

  摘要：

  本文描述了一些PGD2受体拮抗剂化合物。还描述了包括上述PGD2受体拮抗剂在内的药物组合物和药物，以及使用这些PGD2受体拮抗剂的方法，单独或与其他化合物结合，用于治疗呼吸系统、心血管系统和其他PGD2依赖性或PGD2介导的疾病或症状。

  公开号：

  US08497381B2

文献信息

• ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS
  申请人：Hutchinson John Howard

  公开号：US20110021573A1

  公开（公告）日：2011-01-27

  Described herein are compounds that are antagonists of PGD 2 receptors. Also described are pharmaceutical compositions and medicaments that include the antagonists of PGD 2 receptors described herein, as well as methods of using such antagonists of PGD 2 receptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD 2 -dependent or PGD 2 -mediated conditions or diseases.

  本文描述了一些PGD2受体拮抗剂化合物。还描述了包括本文所述的PGD2受体拮抗剂在内的药物组合物和药物，以及使用这些PGD2受体拮抗剂的方法，单独或与其他化合物结合，用于治疗呼吸系统、心血管系统和其他PGD2依赖性或PGD2介导的疾病或病症。
• US8497381B2
  申请人：——

  公开号：US8497381B2

  公开（公告）日：2013-07-30
• [EN] ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS<br/>[FR] ANTAGONISTES DES RÉCEPTEURS D2 DE LA PROSTAGLANDINE
  申请人：AMIRA PHARMACEUTICALS INC

  公开号：WO2009108720A2

  公开（公告）日：2009-09-03

  Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the antagonists of PGD2 receptors described herein, as well as methods of using such antagonists of PGD2 receptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.
• Discovery and optimization of a biphenylacetic acid series of prostaglandin D2 receptor DP2 antagonists with efficacy in a murine model of allergic rhinitis
  作者：Jill M. Scott、Christopher Baccei、Gretchen Bain、Alex Broadhead、Jilly F. Evans、Patrick Fagan、John H. Hutchinson、Christopher King、Daniel S. Lorrain、Catherine Lee、Peppi Prasit、Pat Prodanovich、Angelina Santini、Brian A. Stearns

  DOI：10.1016/j.bmcl.2011.01.024

  日期：2011.11

  Biphenylacetic acid (5) was identified through a library screen as an inhibitor of the prostaglandin D-2 receptor DP2 (CRTH2). Optimization for potency and pharmacokinetic properties led to a series of selective CRTH2 antagonists. Compounds demonstrated potency in a human DP2 binding assay and a human whole blood eosinophil shape change assay, as well as good oral bioavailability in rat and dog, and efficacy in a mouse model of allergic rhinitis following oral dosing. (C) 2011 Published by Elsevier Ltd.
• Antagonists of prostaglandin D2 receptors
  申请人：Hutchinson John Howard

  公开号：US08497381B2

  公开（公告）日：2013-07-30

  Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the antagonists of PGD2 receptors described herein, as well as methods of using such antagonists of PGD2 receptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.

  本文描述了一些PGD2受体拮抗剂化合物。还描述了包括上述PGD2受体拮抗剂在内的药物组合物和药物，以及使用这些PGD2受体拮抗剂的方法，单独或与其他化合物结合，用于治疗呼吸系统、心血管系统和其他PGD2依赖性或PGD2介导的疾病或症状。